Making Better Tomorrow, Bukwang Pharmaceutical. Bukwang R&D
NEWS

Bukwang announces patent registration of SOL-804 in 32 countries

[August 05, 2022]

Bukwang Pharmaceutical Co., Ltd. (Bukwang) announced that the composition patent for SOL-804, a prostate cancer treatment of its subsidiary, Dyna Therapeutics, has been recently registered in 6 more countries this year. The patent is registered in 32 countries, Korea, Japan, United States, Eurasia (2 countries), Europe (20 countries), Australia, Mexico, Singapore, South Africa, India, Canada, and Israel. SOL-804 is an improved version of currently available drugs that aim to improve absorption and food effects, which are the weakness of currently available...

R&D

Bukwang announces patent registration of SOL-804 in 32 countries

[August 05, 2022]

Bukwang Pharmaceutical Co., Ltd. (Bukwang) announced that the composition patent for SOL-804, a prostate cancer treatment of its subsidiary, Dyna...

COMPANY

Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years. Since Bukwang was listed in the Korea Stock Exchange...

Conterapharma
콘테라로고.jpg

Unlocking science for treating neurological disorders

   

Discover Bukwang

PRODUCTS
main_cg.jpg
|    ​Korean    |